BERKELEY
HEIGHTS, NJ - November 26, 2007
- Genta Incorporated (NASDAQ: GNTA) announced today that the
Company's Chairman and Chief Executive Officer, Dr. Raymond P.
Warrell, Jr., will provide a company overview and update of
corporate activities at the Lazard Capital Markets 4th Annual
Healthcare Conference. Genta's presentation is scheduled for
Wednesday, November 28th at 8:00 am EST at the New York Palace
Hotel, New York, NY.
About
Genta
Genta Incorporated is a biopharmaceutical company with a
diversified product portfolio that is focused on delivering
innovative products for the treatment of patients with cancer.
The Company's research platform is anchored by two major
programs: DNA/RNA-based Medicines and Small Molecules. Genasense®
(oblimersen sodium) Injection is the Company's lead compound from
its DNA/RNA Medicines program. Genta is currently recruiting
patients for a global Phase 3 trial of Genasense in patients with
advanced melanoma. The leading drug in Genta's Small Molecule
program is Ganite® (gallium nitrate injection), which the Company
is exclusively marketing in the U.S. for treatment of symptomatic
patients with cancer related hypercalcemia that is resistant to
hydration. The Company has developed G4544, an oral
formulation of the active ingredient in Ganite, which is currently
undergoing initial clinical trials as a potential treatment for
diseases associated with accelerated bone loss. Both Ganite®
and Genasense® are available on a "named-patient" basis in
countries outside the United States. For more information
about Genta, please visit our website at: www.genta.com.
Safe Harbor
This press release may contain forward-looking statements
with respect to business conducted by Genta Incorporated. By
their nature, forward-looking statements and forecasts involve
risks and uncertainties because they relate to events and depend
on circumstances that will occur in the future.
Forward-looking statements include, without limitation,
statements about:
-
the Company's ability to obtain necessary regulatory
approval for Genasense® from the U.S. Food and Drug
Administration ("FDA") or European Medicines Agency
("EMEA");
-
the safety and efficacy of the Company's products or
product candidates;
-
the Company's assessment of its clinical trials;
-
the commencement and completion of clinical trials;
-
the Company's ability to develop, manufacture, license and
sell its products or product candidates;
-
the Company's ability to enter into and successfully
execute license and collaborative agreements, if any;
-
the adequacy of the Company's capital resources and cash
flow projections, and the Company's ability to obtain
sufficient financing to maintain the Company's planned
operations;
-
the adequacy of the Company's patents and proprietary
rights;
-
the impact of litigation that has been brought against the
Company and its officers and directors and any proposed
settlement of such litigation;
-
the Company's ability to retain compliance with the
NASDAQ's listing qualifications; and
-
the other risks described under Certain Risks and
Uncertainties Related to the Company's Business, as contained
in the Company's Annual Report on Form 10-K and Quarterly
Report on Form 10-Q.
The Company does not undertake to update any forward-looking
statements. There are a number of factors that could
cause actual results and developments to differ materially.
For a discussion of those risks and uncertainties, please see the
Company's Annual Report on Form 10-K for 2006 and its most recent
quarterly report on Form 10-Q.
CONTACT:
Nichol Harber
Genta Investor Relations
info@genta.com
908-286-3980
